← Evidence map

ArticleThe Lancet regional health. Western Pacific2025

Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464.

Yuji Hiromatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464. | Socratic